Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:ETrE(11Z,14Z,17Z))

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST000916 AN001491 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma Blood Human Fatty liver disease LIPID MAPS nM
ST000917 AN001497 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine Urine Human Fatty liver disease LIPID MAPS nM
ST001098 AN001786 Metabolomics of Metabolic Risk in Patients Taking Atypical Antipsychotics (part II) Blood Human Schizophrenia University of Michigan nmol
ST002063 AN003362 Intravenous lipopolysaccharide infusion and the bovine metabolome Blood Cow Hyperlipidemia Cornell University Normalized ion intensity
ST000233 AN000350 Metabolomics Reveals that Aryl Hydrocarbon Receptor Activation by Environmental Chemicals Induces Systemic Metabolic Dysfunction in Mice (Part II) Mouse Pennsylvania State University Peak area
ST000403 AN000643 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000414 AN000656 Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000539 AN000819 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000546 AN000833 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST001274 AN002115 Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) Cultured cells Trypanosoma brucei Sleeping sickness Monash University Peak height
ST001275 AN002116 Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II) Cultured cells Trypanosoma brucei Sleeping sickness Monash University Peak height
ST001201 AN001999 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001201 AN001999 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001205 AN002007 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001205 AN002007 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST000915 AN001485 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver Liver Human Fatty liver disease LIPID MAPS pmol/mg
ST002309 AN003772 Targeting malaria parasites with novel derivatives of azithromycin Blood Plasmodium falciparum Malaria Monash University relative intensity
ST001175 AN001951 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University Signal Intensity
ST001315 AN002190 Retargeting azithromycin-like compounds as antimalarials with dual modality Blood Plasmodium falciparum Malaria Monash University Signal Intensity
  logo